{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-111310","form_type":"8-K","ticker":"TVRD","cik":"0001346830","company_name":"Tvardi Therapeutics, Inc.","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.205415+00:00","generated_at":"2026-05-16T20:12:45.014002+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Tvardi Q3 net loss $5.5M; IPF trial fails, HCC data due H1 2026","bullets":["Q3 net loss of $5.5M ($0.59/share), roughly flat YoY; cash $36.5M, runway into Q4 2026.","Phase 2 REVERT Liver Cancer (TTI-101) topline data expected H1 2026; interim showed activity.","TTI-109 healthy volunteer study started; results also H1 2026.","REVERT IPF trial preliminary data in October did not meet goals; further analysis underway.","R&D expenses $3.6M, down from $4.8M; G&A $2.3M, up from $0.9M."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-111310","json":"https://secwatch.observer/filing/0001104659-25-111310.json","markdown":"https://secwatch.observer/filing/0001104659-25-111310.md","text":"https://secwatch.observer/filing/0001104659-25-111310.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1346830/000110465925111310/0001104659-25-111310-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1346830/000110465925111310/tm2531079d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:12:45.014002+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}